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Abstract
Background: Alzheimer’s disease (AD) pathology appears several years before clinical symptoms, so identifying
ways to detect individuals in the preclinical stage is imperative. The cerebrospinal fluid (CSF) Tau/Aβ42 ratio is
currently the best known predictor of AD status and cognitive decline, and the ratio of CSF levels of chitinase-3-like
1 protein (CHI3L1, YKL-40) and amyloid beta (Aβ42) were reported as predictive, but individual variability and group
overlap inhibits their utility for individual diagnosis making it necessary to find ways to improve sensitivity of these
biomarkers.
Methods: We used linear regression to identify genetic loci associated with CSF YKL-40 levels in 379 individuals
(80 cognitively impaired and 299 cognitively normal) from the Charles F and Joanne Knight Alzheimer’s Disease
Research Center. We tested correlations between YKL-40 and CSF Tau/Aβ42 ratio, Aβ42, tau, and phosphorylated
tau (ptau181). We used studentized residuals from a linear regression model of the log-transformed, standardized
protein levels and the additive reference allele counts from the most significant locus to adjust YKL-40 values and
tested the differences in correlations with CSF Tau/Aβ42 ratio, Aβ42, tau, and ptau181.
Results: We found that genetic variants on the CH13L1 locus were significantly associated with CSF YKL-40 levels,
but not AD risk, age at onset, or disease progression. The most significant variant is a reported expression
quantitative trait locus for CHI3L1, the gene which encodes YKL-40, and explained 12.74 % of the variance in CSF
YKL-40 in our study. YKL-40 was positively correlated with ptau181 (r = 0.521) and the strength of the correlation
significantly increased with the addition of genetic information (r = 0.573, p = 0.006).
Conclusions: CSF YKL-40 levels are likely a biomarker for AD, but we found no evidence that they are an AD
endophenotype. YKL-40 levels are highly regulated by genetic variation, and by including genetic information the
strength of the correlation between YKL-40 and ptau181 levels is significantly improved. Our results suggest that
studies of potential biomarkers may benefit from including genetic information.
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Background
Since it has been well demonstrated that Alzheimer’s
disease (AD) pathology is present long before any clinical
symptoms, emphasis has been on improving identification
of those in this preclinical stage [1–3]. Studies have found
that the ratio of cerebrospinal fluid (CSF) tau to Aβ42 is a
better predictor of AD status and cognitive decline than
either of these proteins individually and improves discrim-
ination of AD from other dementias such as vascular de-
mentia and frontotemporal lobar degeneration [4–6]. CSF
levels of tau correlate with the amount of neurodegenera-
tion, phosphorylated tau (ptau) levels correlate with tangle
pathology, and Aβ42 levels inversely correlate with the
amount of plaques, which makes these ideal biomarkers
for AD pathology [3, 7]. Studies have focused on targeting
Aβ, tau, or both proteins as potential treatments for AD,
making it necessary to find alternative biomarkers that are
not being directly targeted [8–11]. CSF levels of YKL-40
are a promising biomarker for AD; they are significantly
higher in individuals with AD dementia than in cognitively
normal individuals [12]. CSF YKL-40 is also associated
with cortical thinning in cognitively normal individuals
with low levels of CSF Aβ42 who are at risk for AD, and
highly correlates with CSF ptau [13]. YKL-40 is a
secreted glycoprotein, encoded by chitinase-3-like 1
protein (CHI3L1), expressed in astrocytes and associ-
ated with neuroinflammatory response. Although the
exact function of YKL-40 is unknown, it has been asso-
ciated with many immune and inflammatory diseases as
well as several cancers [14, 15]. Studies have shown that
CSF levels of YKL-40 can be used to distinguish AD
from non-AD dementia, Parkinson’s disease, dementia
with Lewy bodies, and to distinguish between mild cog-
nitive impairment (MCI) that progresses to AD vs MCI
not due to AD indicating that CSF YKL-40 is not sim-
ply a marker for inflammation due to neurodegenera-
tion but may be specific enough for AD [16, 17].
However, due to individual variability and group over-
lap in these CSF protein levels, further studies are ne-
cessary to find ways to improve sensitivity and
specificity for AD. We hypothesized that adding genetic
information may provide a means to improve specificity
and sensitivity of CSF YKL-40 as a biomarker for AD.
One key feature of endophenotypes is that they have
a clear genetic connection with the trait of interest, and
for a biomarker to be considered an endophenotype it
has to be measureable, heritable, and segregate with
status. The genetic connection between endopheno-
types and complex traits has been demonstrated to pro-
vide power in genetic studies to identify novel variants
and inform about possible underlying biology [18, 19].
CSF levels of tau, ptau181, Aβ42 are well-established AD
endophenotypes and have allowed us to identify novel
variants associated not only with tau and ptau181 levels
but also with AD risk, tangle pathology, and cognitive de-
cline [18]. Recent research suggests that neuroinflamma-
tion is not merely a by-product of neurodegeneration in
AD but may play a key role in pathology [20]. Since CSF
levels of YKL-40 can distinguish between AD and non-
AD MCI, perhaps the unknown function of YKL-40 in
neuroinflammation is involved in the progression of path-
ology. If polymorphisms regulating YKL-40 also contrib-
ute to some aspect of AD such as risk, age at onset, or
cognitive decline then understanding their genetic regula-
tion can help provide insights into biological mechanisms
underlying AD, and can help to determine whether YKL-
40 is really involved in the pathogenesis (endophenotype)
or is just a biomarker for the disease.
First we performed single variant genetic analyses of
CSF levels of YKL-40 to identify single nucleotide poly-
morphisms (SNPs) associated with YKL-40 levels. Next
we analyzed whether genome-wide significant variants
from our analyses were also associated with AD risk, age
at onset, or progression. Finally, we tested correlations
between YKL-40 and the CSF Tau/Aβ42 ratio, Aβ42, tau,
and ptau181, before and after including genetic informa-
tion for YKL-40 levels, to determine if adding genetic in-




The Washington University Institutional Review Board
approved this study. Written informed consent was
obtained from participants or their family members.
Study participants
All 379 individuals with measured CSF levels of YKL-
40 were from the Charles F. and Joanne Knight Alzheimer’s
Disease Research Center (Knight-ADRC; Table 1).
Dementia severity was determined using the Clinical
Dementia Rating (CDR) where 0 indicates cognitive
normality, 0.5 is defined as very mild dementia, 1 is
mild dementia, 2 is moderate dementia, and 3 is severe
dementia [21]. There were 80 cases, defined as individ-
uals with CDR > 0 at lumbar puncture, and 299 cogni-
tively normal controls (CDR = 0 at lumbar puncture;
Table 1). Neuropsychological and clinical assessments
were collected for all participants and CSF was collected
in the morning after an overnight fast, processed, and
stored at -80 °C, as described previously [22]. Individuals
were evaluated by Clinical Core personnel at Washington
University.
Genotyping and quality control
The samples were genotyped with the Illumina 610 or
Omniexpress chip. Stringent quality control criteria
were applied to each genotyping array separately before
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combining data. A ≤98 % call rate was applied for single
nucleotide polymorphisms (SNPs) and individuals.
SNPs not in Hardy-Weinberg equilibrium (p < 1 × 10-6)
or with MAF <0.02 were excluded. X-chromosome SNPs
were analyzed to verify gender identification. Pairwise
genome-wide estimates of proportion identity-by-descent
were used to find duplicate and related individuals which
were eliminated from the analysis. Principal components
were calculated using EIGENSTRAT [23] to confirm eth-
nicity of each sample. Imputation was performed as de-
scribed previously [18]. Briefly, BEAGLE v3.3.1 software
[24] and the 1,000 genome data were used to impute up
to 6 million SNPs. There were 5,986,883 imputed and
genotyped SNPs after removing SNPs with a call rate
<95 % or a BEAGLE r2 ≤ 0.3.
Analyte measurements and quality control
The Knight-ADRC Biomarker Core measured CSF levels
of Aβ42, tau, and ptau181 using single-analyte enzyme-
linked immunosorbent assays (ELISA) as described previ-
ously [22]. CSF YKL-40 levels were measured using the
MicroVue ELISA (Quidel) as described previously [12].
Statistical analyses
Log-transformed, standardized values for CSF YKL-40
levels were tested for normality using the Shapiro-Wilk
test. We used R v3.2.1 [25] to perform linear regression
to determine if CSF levels of YKL-40 were influenced by
age, gender, or sample batch (Additional file 1: Table
S1). Age, gender, and sample batch were used as covari-
ates to test association of YKL-40 with cognitive status.
Correlations of CSF levels of YKL-40 with CSF Aβ42,
tau, ptau181, and Tau/Aβ42 ratio were calculated using
Pearson’s correlation.
Genetic association with CSF levels of YKL-40 were
tested using an additive model in PLINK v1.9 (http://
www.cog-genomics.org/plink2) [26]. Covariates used were
sample batch, age, gender, and two principal component
factors for population structure. Statistical significance for
single variant association was defined as p < 5 × 10-8 based
on the commonly used threshold considered appropriate
for the likely number of independent tests with Bonferroni
correction. The threshold of p < 1 × 10-5 was defined for
suggestive association. The genomic inflation factor for
association with YKL-40 levels was 1, suggesting no evi-
dence of inflation due to population stratification. SNP
annotation was performed using ANNOVAR version
2015-06-17 [27] and the NCBI Database of Single
Nucleotide Polymorphisms (dbSNP) Build ID: 142
(http://www.ncbi.nlm.nih.gov/SNP) [28]. RegulomeDB
v1.1 (http://regulome.stanford.edu/index) [29] was used
to determine if SNPs of interest were potential regula-
tory elements. The Genotype-Tissue Expression (GTEx)
Analysis Release V6, dbGaP Accession phs000424.v6.p1
(http://www.gtexportal.org) [30] was used to determine
if SNPs of interest were potential expression quantita-
tive trait loci (eQTLs).
Disease progression was modeled as the change in
CDR Sum of Boxes (CDR-SB) per year. A total of 1,646
individuals from longitudinal studies of AD patients with
≥3 clinical assessments over 1.5 years after being diag-
nosed with AD were included in the analysis. A mixed-
model repeated measure framework was used to account
for correlation between repeated measures in the same
individual. Age, sex, baseline CDR, follow-up time, level
of education, site, and PCs were included as covariates.
The appropriate optimal variance-covariance structure
that minimizes the Akaike Information Criterion for
testing the null model AR1 was selected [31].
To estimate the proportion of variance in CSF levels
of YKL-40 explained by genetic variants we used the
coefficient of determination (R2) of a linear model of
the log-transformed, standardized CSF protein levels
and the additive reference allele counts of the top
genome-wide associated SNP (rs10399931) with sample
batch, age, and gender as covariates and subtracted the
R2 of a linear model with the log-transformed, stan-
dardized CSF protein levels and the covariates in the
null model. To adjust CSF levels of YKL-40 for genetic
effect, we used studentized residuals from a linear re-
gression model of the log-transformed, standardized
protein levels and the additive reference allele counts of
rs10399931. Age, gender, and sample batch were used
as covariates to test association of the adjusted levels of
YKL-40 with AD status. Correlations of the adjusted
levels of YKL-40 with CSF Aβ42, tau, ptau181, and tau/
Aβ42 ratio were determined using Pearson’s correlation
(r). The R package cocor version 1.1-1 [32] was used to
compare correlations between CSF Aβ42, tau, ptau181,
and tau/Aβ42 ratio and adjusted or unadjusted CSF pro-
tein levels. We reported the results using the Meng Z-test
model [33], but the results for all models reported by
cocor were comparable.
See Additional file 2: Supplementary Methods and
Results for gene ontology over-representation and tissue-
specific expression analyses.
Table 1 Characteristics of CSF YKL-40 data
Knight-ADRC
Samples 379
Age in years (mean ± SD) 70.86 ± 8.80
(range) 49–91
Gender (M/F) 148/231
% CDR >0 21.11
% APOE E4 36.68
CSF YKL-40 (ng/mL) 307.25 ± 108.45
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Results
CSF levels of YKL-40 in AD cases vs controls
After applying stringent quality control, our dataset con-
tained CSF levels of YKL-40 for 379 individuals from the
Charles F. and Joanne Knight Alzheimer’s Disease Re-
search Center (Knight-ADRC; Table 1). We used logistic
regression including age, gender, and sample batch as
covariates to test whether levels of YKL-40 were associ-
ated with AD status defined by CDR. Cases (defined by
CDR at lumbar puncture >0) had significantly higher
CSF levels of YKL-40 than controls (cases: 366.37 ±
136.48 ng/mL; controls: 290.18 ± 92.44 ng/mL; p = 0.015,
β = 0.698; Additional file 3: Figure S1). We used linear
regression to test if APOE genotype influenced YKL-40
and found there was no effect on YKL-40 levels (p =
0.704). Several studies indicate that CSF Tau/Aβ42 ratio
is a better predictor of disease status than clinical assess-
ment [5, 6]. We tested the correlation between CSF Tau/
Aβ42 ratio and YKL-40. Levels of YKL-40 were positively
correlated with CSF Tau/Aβ42 ratio (p = 2.61 × 10
-8, r =
0.318), most likely due to the positive correlation with
tau (p = 7.06 × 10-22, r = 0.522) since tau and Tau/Aβ42
ratio are highly correlated (p = 3.99 × 10-52, r = 0.736)
and although there is a high negative correlation be-
tween Tau/Aβ42 ratio and Aβ42 levels (p = 3.07 × 10
-64, r
= -0.788), YKL-40 was not correlated with Aβ42 (p =
0.838, r = 0.012; Table 2 and Additional file 4: Figure S2).
Single variant analysis of CSF YKL-40 levels
To determine whether genetic variants are associated
with levels of YKL-40, we used linear regression to test
the additive genetic model of each single nucleotide
polymorphism (SNP) for association with CSF protein
levels using age, gender, sample batch, and two princi-
pal component factors for population stratification as
covariates. We found 14 genome-wide significant SNPs
associated with YKL-40, all in the CHI3L1 locus. The
most significant SNP was rs10399931, a variant <200 bp
upstream of the transcription start site for CHI3L1
(genotyped, p = 1.76 × 10-14, β = -0.575, minor allele fre-
quency (MAF) = 0.244; Fig. 1 and Additional file 5:
Table S2). We did not find any additional genome-wide
significant loci when we ran the analysis conditioned
on rs10399931. Data from RegulomeDB [29] indicates that
rs10399931 is likely to affect binding and gene expression;
two RNA-Seq studies and the Genotype-Tissue Expression
(GTEx) database have reported rs10399931 is an eQTL
for CHI3L1 (whole blood: p = 1.7 × 10-11, β = -0.35;
transformed fibroblasts: p = 3.1 × 10-11, β = -0.37; thy-
roid: p = 5.7 × 10-10, β = -0.42; lung: p = 6.7 × 10-9, β
= -0.37; tibial nerve: p = 8.1 × 10-9, β = -0.33; subcutane-
ous adipose: p = 5.5 × 10-7, β = -0.28; tibial artery: p =
2.4 × 10-6, β = -0.26) [30, 34, 35]. CHI3L1 variants have
been associated with YKL-40 levels in serum previously
[36], but to our knowledge this is the first time it has
been reported to be associated with CSF levels of YKL-
40. We calculated what proportion of variance in CSF
YKL-40 levels was explained by rs10399931. Age, gen-
der, and sample batch explained 14.89 % of the variance
in YKL-40 levels, and addition of the rs10399931 effect
explained another 12.74 % of the variance. As a com-
parison, a previous GWAS study of CSF levels of tau
and ptau181 estimated that the genetic effect of the
genome-wide significant association located in apolipo-
protein E (APOE) explained only 0.25–0.29 % of the
variability of tau and ptau181 levels [18]. Additionally,
we found a signal in chromosome 13 (rs78081700, p =
6.26 × 10-8, β = 0.636, Fig. 1 and Additional file 5: Table
S2) that almost reached genome-wide significance and
another eight loci with suggestive p values (Fig. 1 and
Additional file 5: Table S2), indicating that additional loci/
genes could be associated with CSF YKL-40, although a
larger sample size would be needed to confirm this
hypothesis.
Association of GWAS hits and pathways with AD risk, age
at onset, and disease progression
To determine if our genome-wide significant SNPs were
also associated with risk for AD we searched the results
from a GWAS previously published by the Inter-
national Genomics of Alzheimer’s Project (I-GAP)
consisting of a total 25,580 AD cases and 48,466 con-
trols [37]. None of our genome-wide significant SNPs
had significant p-values in the I-GAP results (rs10399931:
p = 0.763, β = 0.006; Table 3). Based on analyses of data
from a previously published GWAS investigating genetic
Table 2 Correlations of CSF levels of YKL-40 with CSF Tau/Aβ ratio, AB42, ptau181, and tau levels before and after adjusting for top
SNP effect
CSF Tau/Aβ ratio CSF Aβ42 levels CSF ptau181 levels CSF tau levels
p r p r p r p r
CSF YKL-40 2.61×10-8 0.318 0.838 0.012 8.98×10-22 0.521 7.06×10-22 0.522
CSF YKL-40-rs10399931 effect 5.28×10-10 0.357 0.972 0.002 2.82×10-26 0.573 1.66×10-26 0.575
p 95 % CI p 95 % CI p 95 % CI p 95 % CI
Correlation difference (Meng Z-test) 0.071 -0.083, 0.003 0.661 -0.031, 0.049 0.006 -0.116, -0.020 0.006 -0.116, -0.020
95 % CI: 95 % confidence interval, null hypothesis was retained if interval included 0
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variants associated with age at onset for AD [38] our
genome-wide significant SNPs did not appear to be associ-
ated with age at onset (rs10399931: p = 0.197, β = 0.026;
Table 3). We also found that our genome-wide significant
SNPs were not significantly associated with advancement
in CDR (rs10399931: p = 0.142, β = -0.072; Table 3). Re-
cently the I-GAP published results from a study of bio-
logical pathways and gene expression networks associated
with AD [39]. None of the gene ontology terms that were
enriched in our gene ontology analyses of GWAS results
for YKL-40 (Additional file 6: Table S3) were found in the
I-GAP report [39]. Together these data suggest that YKL-
40 may be a promising biomarker for AD, but probably
not an endophenotype.
Improving CSF biomarkers and CSF YKL-40 utility by
including genetic information
Because the genome-wide significant SNPs are not asso-
ciated with disease status but explain a large proportion
of the CSF levels of YKL-40, we hypothesized that by
accounting for genetic information, it would be possible
to improve the efficacy of these measures as biomarkers.
Levels of YKL-40 have been reported to be correlated
with CSF levels of tau and ptau181 but not Aβ42, and this
was replicated in our analyses (Table 2 and Additional
file 4: Figure S2) [12, 15].
We decided to focus on CSF ptau181 and YKL-40 since
these were highly correlated and the results were similar
for tau. First we used linear regression to determine
whether rs10399931 genotype influenced ptau181 levels
(p = 0.782, R2 = -0.005). Then we included the additive
model for rs10399931 in YKL-40 levels and re-analyzed
the correlation with ptau181. The correlation coefficient
for the adjusted values of CSF YKL-40 levels and ptau181
was higher than the unadjusted values (adjusted: p = 2.82 ×
10-26, r = 0.573 vs. unadjusted: p = 8.98 × 10-22, r = 0.521;
Table 2). We used the R package cocor [32] and deter-
mined that this change in correlation was statistically sig-
nificant (p = 0.006, 95 % CI: -0.116, -0.020; Table 2). Similar
results were found for tau (Table 2). As expected, we did
not find any significant difference in the correlation be-
tween Aβ42 and the corrected or uncorrected YKL-40
values (Table 2). For CSF Tau/Aβ42 ratio, which is a power-
ful predictor for AD and progression, we found a margin-
ally significant improvement when the genetic information
was included (adjusted: r = 0.357 vs. unadjusted: r = 0.318;
p = 0.071, 95 % CI: -0.083, 0.003, Table 2).
Discussion
AD pathology is present long before any clinical symp-
toms [5, 21, 40–45], and multiple clinical trials are being
performed in pre-symptomatic individuals. However, it is
necessary to have reliable biomarkers to identify these in-
dividuals and to monitor the efficacy of new treatments.
CSF ptau181 and Aβ42 have emerged as the most promis-
ing biochemical biomarkers for AD risk and progression
Fig. 1 Manhattan and regional plots for associations with CSF levels of YKL-40. a Manhattan plot of –log10 p-values for genetic association with
CSF levels of YKL-40; b Regional plot for genome-wide significant association on chromosome 1
Table 3 Association of genome-wide significant locus from CSF YKL-40 GWAS with AD risk, age at onset, and disease progression
CSF YKL-40 AD risk Age at onset Progression
Chr Position SNP A1 MAF p β p β p β p β
1 203156080 rs10399931 T 0.244 1.76×10-14 -0.575 0.763 0.006 0.197 0.026 0.142 -0.072
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[46]. Although these CSF biomarker levels are highly asso-
ciated with AD, there is large inter-individual variability,
and a relatively large overlap in the absolute CSF levels
between cases and controls. Additionally, if treatments
directly target tau proteins or Aβ42, the CSF levels may no
longer be an informative biomarker because the treatment
could affect those levels separately from disease state.
Therefore, the identification of surrogates for Aβ42 and
tau and novel approaches to improve accuracy of CSF bio-
markers that can control for the individual inter-variability
can have a large impact on clinical trials as well as in the
general practice.
CSF YKL-40 has emerged as a novel potential bio-
marker for AD, as it is higher in individuals with AD
than in cognitively normal individuals and is highly cor-
related with CSF ptau181 levels [2, 12, 13, 15]. However,
it is not clear whether CSF YKL-40 is simply a bio-
marker or also an endophenotype for AD. Biomarkers
are measurable biological characteristics that can be
used as indicators of complex traits, but don’t necessar-
ily provide information about the biology of the trait.
They may simply be influenced by the same biological
processes rather than being part of those processes.
Endophenotypes are biomarkers that are heritable traits
with a genetic connection with disease, can be measured
in all individuals regardless of disease status, and there-
fore can be highly informative about the biological
causes of the disease.
In this study, we used genomic approaches to deter-
mine whether CSF YKL-40 is an endophenotype for AD,
and whether CSF YKL-40 becomes more informative by
adding genetic information. Here we reported for the
first time a genetic analysis for CSF YKL-40 levels. We
found a genome-wide significant signal on CHI3L1,
which encodes YKL-40 (rs10399931: p = 1.76 × 10-14,
MAF = 0.24), and multiple suggestive signals on other
chromosomes. Interestingly, rs10399931 alone explains
almost as much of the variance in YKL-40 levels (R2 =
0.127) as both age and gender combined (R2 = 0.149).
Neither this variant or any of the suggestive variants
were associated with AD risk, age at onset, or disease
progression, indicating that CSF YKL-40 is probably not
an endophenotype for AD.
Because of the large proportion of CSF YKL-40 variabil-
ity explained by rs10399931, we analyzed whether the cor-
relation with CSF ptau181 improves when including the
genotypic information for this variant. We hypothesize
that in order to use genetic information to improve bio-
marker efficacy, the genetic association must be strong
and replicable. We also predict that the improvement of
the efficacy of the biomarker could be correlated with the
proportion of biomarker level variability explained by the
genetic variant. Additionally, if multiple loci are signifi-
cantly associated with biomarker levels, a polygenic risk
score should provide better performance than single locus
analyses. As hypothesized, we found a significant increase
in the correlation of CSF YKL-40 with tau and ptau181
when genetic information for rs10399931 was included in
the model. The correlation with the Tau/Aβ42 ratio also
improved, although it did not reach statistical significance.
Based on these results, we hypothesize that the addition of
genotypic information could significantly increase the sen-
sitivity and specificity of biomarkers, but strong genetic
associations are needed. When multiple loci are associated
with biomarker levels, genetic risk scores would probably
provide better results.
Additionally, we think this approach for improving
biomarker efficacy by adjusting for genetic effect would
only be effective for biomarkers, as may be the case for
YKL-40, and not for informative endophenotypes such
as CSF levels of Aβ42 and tau. Genetic variants associ-
ated with endophenotype values are very likely to be as-
sociated with disease risk as well, as has been found
previously in the case of AD endophenotypes [18, 47].
Therefore, correcting for genetic variants associated with
endophenotype levels would generate a co-linearity prob-
lem and not improve, but actually worsen, the biomarker
performance in that case.
Conclusions
Our genetic analyses indicate that although CSF YKL-40
levels are a promising biomarker for AD, there is no evi-
dence they are an AD endophenotype. Genetic variation
highly regulates CSF YKL-40 levels, and by including gen-
etic information, the correlations with CSF tau and
ptau181 levels increase. Although additional studies are
needed to confirm our hypothesis, our results suggest that
studies of potential biomarkers for complex traits may
benefit from correction of genetic effects on biomarker
levels. This could be particularly important when using
biomarkers as surrogate endpoints in clinical trials.
Additional files
Additional file 1: Table S1. Covariate associations with CSF YKL-40.
Results (p-value and adjusted R2) from regression of potentially confounding
covariates: age at lumbar puncture, gender, and sample batch. Only age
appeared significantly associated with CSF levels of YKL-40 (p = 1.19 × 10-18,
R2 = 0.184). (DOCX 16 kb)
Additional file 2: Supplementary Methods and Results. Methods and
results for the gene ontology over-representation analyses of top SNPs
from the single variant analysis of CSF YKL-40 levels. 70 genes mapped to
the top SNPs (p < 1 × 10-4) were significantly enriched in human brain
and pituitary tissue at all levels of specificity. Figure illustrates the different
human tissues with expression data available with Benjamini-Hochberg
corrected p < 0.10 in the enrichment analysis and the Table shows the re-
sults for all tissues with uncorrected p < 0.05 in at least one specificity
index. The specificity index represents how specific a set of genes are to
a particular tissue. (DOCX 163 kb)
Additional file 3: Figure S1. Beeswarm plot of the normalized CSF
YKL-40 levels in cases (defined as CDR > 0 at time of lumbar puncture)
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compared to controls (CDR = 0 at time of lumbar puncture). p = 0.015.
(DOCX 119 kb)
Additional file 4: Figure S2. Scatterplots of correlations between
normalized values of CSF YKL-40 and Tau/Aβ42 ratio, levels of Aβ42,
ptau181, and tau. Pearson’s correlation (r). CSF YKL-40 positively correlated
with Tau/Aβ42 ratio (a), ptau181 (c), and tau (d), but was not correlated
with Aβ42 (b). (DOCX 89 kb)
Additional file 5: Table S2. YKL-40 single variant analysis top loci
(p < 1 × 10-5). Chr = chromosome, bp position = base pair position,
SNP = rs ID for single nucleotide polymorphism, MAF = minor allele
frequency (also effect allele), Gene = nearest gene. Chromosome
and base pair position based on Build 37 of reference genome.
(DOCX 14 kb)
Additional file 6: Table S3. Top gene ontology categories (p < 0.05) in
both CPDB and PANTHER over-representation analyses of YKL-40 GWAS
results (p < 1 × 10-4). GO ID = Identification number from the Gene Ontology
Consortium, CPDB = Consensus Path Database, PANTHER = Protein Analysis
Through Evolutionary Relationships. Thirteen gene ontology terms had
p < 0.05 in both analyses. (DOCX 13 kb)
Abbreviations
AD: Alzheimer’s disease; APOE: Apolipoprotein E; Aβ42: Amyloid beta (1-42);
CDR: Clinical dementia rating; CDR-SB: CDR Sum of Boxes; CHI3L1: Chitinase-
3-like 1; CSF: Cerebrospinal fluid; ELISA: Enzyme-linked immunosorbent assay;
eQTL: Expression quantitative trait locus; GWAS: Genome-wide association
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